A multicenter randomized placebo controlled trial of rifampin to reduce pedal amputations for osteomyelitis in veterans with diabetes (VA INTREPID)
Open Access
- 8 January 2020
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 20 (1) , 1-12
Abstract
Background: The prevalence of diabetes mellitus continues to inexorably rise in the United States and throughout the world. Lower limb amputations are a devastating comorbid complication of diabetes mellitus. Osteomyelitis increases the risk of amputation fourfold and commonly presages death. Antimicrobial therapy for diabetic foot osteomyelitis (DFO) varies greatly, indicating that high quality data are needed to inform clinical decision making. Several small trials have indicated that the addition of rifampin to backbone antimicrobial regimens for osteomyelitis outside the setting of the diabetic foot results in 28 to 42% higher cure rates. Methods/design: This is a prospective, randomized, double-blind investigation of the addition of 6 weeks of rifampin, 600 mg daily, vs. matched placebo (riboflavin) to standard-of-care, backbone antimicrobial therapy for DFO. The study population are patients enrolled in Veteran Health Administration (VHA), ages ≥18 and ≤ 89 years with diabetes mellitus and definite or probable osteomyelitis of the foot for whom an extended course of oral or intravenous antibiotics is planned. The primary endpoint is amputation-free survival. The primary hypothesis is that using rifampin as adjunctive therapy will lower the hazard rate compared with the group that does not use rifampin as adjunctive therapy. The primary hypothesis will be tested by means of a two-sided log-rank test with a 5% significance level. The test has 90% power to detect a hazard ratio of 0.67 or lower with a total of 880 study participants followed on average for 1.8 years. Discussion: VA INTREPID will test if a rifampin-adjunctive antibiotic regimen increases amputation-free survival in patients seeking care in the VHA with DFO. A positive finding and its adoption by clinicians would reduce lower extremity amputations and their associated physical and emotional impact and reduce mortality for Veterans and for the general population with diabetic foot osteomyelitis. Given that rifampin-adjunctive regimens are currently employed for therapy for the majority of DFO cases in Europe, and only in a small minority of cases in the United States, the trial results will impact therapeutic decisions, even if the null hypothesis is not rejected. Trial registration: Registered January 6, 2017 at ClinicalTrials.gov, NCT03012529.Keywords
Funding Information
- U.S. Department of Veterans Affairs (0000000)
This publication has 27 references indexed in Scilit:
- 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot InfectionsaClinical Infectious Diseases, 2012
- Systemic Antibiotic Therapy for Chronic Osteomyelitis in AdultsClinical Infectious Diseases, 2011
- Scientific and Organizational Collaboration in Comparative Effectiveness Research: The VA Cooperative Studies Program ModelThe American Journal of Medicine, 2010
- Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused byStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2008
- Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatmentDiabetes/Metabolism Research and Reviews, 2008
- Outcome of Diabetic Foot Osteomyelitis Treated NonsurgicallyDiabetes Care, 2008
- An Off-the-Shelf Instant Contact Casting Device for the Management of Diabetic Foot UlcersDiabetes Care, 2007
- Multiple Combination Bactericidal Testing of Staphylococcal Biofilms from Implant-Associated InfectionsAntimicrobial Agents and Chemotherapy, 2006
- Deep Foot Infections in Patients with Diabetes and Foot UlcerJournal of Diabetes and its Complications, 1999
- Chronic Osteomyelitis Caused by Staphylococcus aureus: Controlled Clinical Trial of Nafcillin Therapy and Nafcillin-Rifampin TherapySouthern Medical Journal, 1986